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Abstract Treatment of acromegaly with monotherapy
long-acting somatostatin analogues (LA-SSA) as primary
treatment or after neurosurgery can only achieve complete
normalization of insulin-like growth factor I (IGF-I) in
roughly 40 % of patients. Recently, one of the acromegaly
consensus groups has recommended switching to combined
treatment of LA-SSA and pegvisomant (PEGV) in patients
with partial response to LA-SSAs. This combination of
LA-SSA and PEGV, a growth hormone receptor antago-
nist, can normalize IGF-I levels in virtually all patients,
requiring that the adequate dose of PEGV is used. The
required PEGV dose varies significantly between individ-
ual acromegaly patients. One of the advantages of the
combination therapy is that tumor size control or even
tumor shrinkage can be observed in a vast majority of
patients. The main side effects of the combination treat-
ment are gastrointestinal symptoms, lipohypertrophy and
transient elevated liver transaminases. In this review we
provide an overview of the efficacy and safety of the
combined treatment of LA-SSAs with PEGV.
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Introduction
Acromegaly is a rare disease almost exclusively caused by
a growth hormone (GH) secreting pituitary adenoma. This
hypersecretion of GH and the associated elevated IGF-I
levels result in increased morbidity and mortality [1].
Surgery is in general the first treatment modality, but is not
always successful, as the majority of the patients have a
macroadenoma [1]. The reported cure rates of transsphe-
noidal surgery vary widely, mainly depending on tumor
size and invasiveness and the experience of the neurosur-
geon [2]. Surgery of microadenomas (\1 cm in diameter)
has an average cure rate of 78 %, whereas with
macroadenomas (C1 cm in diameter) the average cure rate
B50 % [2]. However, these previous results were obtained
10 years ago. More recent data from daily practice were
shown in a study with data gathered from the UK National
Acromegaly Registry. This study reported cure rates
between 20 and 40 % [3]. LA-SSAs are currently used as
pre-surgical treatment, adjuvant treatment and as primary
medical treatment. Multiple studies addressed the efficacy
of LA-SSA, and have shown that LA-SSA treatment alone
reached normalization of IGF-I levels in about half of the
patients [4]. No differences between lanreotide SR and
octreotide LAR were observed regarding tumor shrinkage
and normalization of IGF-I levels [5]. An attractive way to
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control biochemical disease activity in patients that are
uncontrolled on LA-SSA monotherapy is to add PEGV,
because of the different modes of action of these two drugs.
LA-SSA reduces hypersecretion of GH by binding to
somatostatin receptors on the pituitary adenoma. PEGV is a
pegylated recombinant analogue of GH and thereby func-
tions as a GH antagonist. It acts by reducing the excessive
GH actions in peripheral tissues and by blocking the
increased production of IGF-I by the liver. Combined
treatment as pre-surgical treatment to improve morbidity is
very questionable, as there are yet no supporting data.
Adjuvant treatment and primary medical treatment are
suitable for LA-SSA combined with PEGV. However, in
the current guidelines combination treatment is only rec-
ommended in partial responders to LA-SSA [6]. A recent
Italian registration study reported that LA-SSA combined
with PEGV is prescribed widely in Italy and more fre-
quently in tertiary than in secondary referral hospitals (59
vs. 37 % of the patients, p\ 0.001). In more experienced
centers less adverse events were reported during PEGV
treatment, however long-term efficacy rates were lower.
The authors suggest for this latter finding an inadequate
patient’s selection due to prevalence of more aggressive
tumors in the tertiary referral centers.
The first clinical PEGV-trials observed high efficacy
rates of 89–97 % depending on dose and duration of the
treatment [7, 8]. The large observational ACROSTUDYTM
could not confirm these high efficacy rates. However, it is
noteworthy that this non-interventional safety surveillance
study was not designed to address efficacy rates, as dose
titration was not part of the study design [9]. The first study
about combined treatment with both LA-SSA and PEGV
was reported in 2005, which observed a high efficacy rate
of 95 % with a lower required PEGV dose to achieve
normalization of IGF-I levels compared to the first data
reporting PEGV monotherapy with a similar efficacy rate
[8, 10]. This high efficacy rate and lower required PEGV
dose during combined treatment was confirmed in later
reports [11–14]. This review will discuss the available
literature on the combination treatment in acromegaly
patients, including level of disease control, tumor size and
side effects.
Efficacy of the combination therapy with LA-SSA
and PEGV
Meta-analyses of clinical trials showed that LA-SSAs alone
normalize GH and IGF-I levels in about 50 % of patients
[4]. However, due to selection bias this efficacy rate is
probably an overestimation. In unselected treatment-naive
patients an LA-SSA efficacy rate of 40 % seems to be more
common [15, 16]. PEGV appears to be more effective, both
during monotherapy as during co-treatment with LA-SSA
[7, 8, 11–14, 17]. Table 1 shows a summary of studies
reporting on efficacy of acromegaly patients using LA-SSA
in combination with PEGV. The efficacy rates during a
period of 9 years in a large Dutch cohort are shown in
Fig. 1 [12]. Because PEGV is a competitive blocker of the
GH receptor (GHR), pharmacology dictates that in prin-
ciple it should be possible to control IGF-I levels in all
patients with acromegaly, provided that the appropriate
PEGV dose is used. LA-SSAs have direct and indirect
effects that result in a GH-independent decrease of IGF-I
production [18, 19]. A Danish study reported that PEGV
serum levels increase by 20 % when combined with LA-
SSA [20]. The appropriate PEGV dose varies among
acromegaly patients, the Dutch cohort reported that
patients using high dose of LA-SSA needed a median
weekly PEGV dose of 80 mg (range: 30–300 mg) to
achieve normal IGF-I levels in 97 % of the patients [12].
Monotherapy of PEGV requires a higher cumulative
weekly dose of around 130 mg to achieve a similar nor-
malization rate after 12 months of treatment [8]. In contrast
to these reports, an Italian observational study reported no
difference in median required PEGV dose to normalize
IGF-I levels in patients using PEGV monotherapy com-
pared to patients treated with the combination therapy [21].
However, these groups were not similar according to
severity of the disease. The PEGV monotherapy group had
significant lower GH and IGF-I levels at baseline compared
to the combination group in this Italian observational study
[21]. Observational registries such as the ACROSTUDYTM
and German Pegvisomant Observational Study (GPOS) [9,
22], in which patients using PEGV are included regardless
their concomitant medication, observed lower efficacy
rates around 60 %, compared with the clinical trials of
PEGV monotherapy and combination treatment mentioned
previously [8, 12]. In the ACROSTUDYTM PEGV was
combined with LA-SSA in 23 %, with dopamine agonist in
6 %, and a combination of the three agents in 4 % of
patients [9]. After 5 years the mean weekly dose was
106 mg in patients with a normal IGF-I, and 113 mg in
those with an elevated IGF-I [23]. However, these studies
were not designed to evaluate efficacy and dose titration,
but aimed for the evaluation of safety aspects, such as rare
side effects. The lower efficacy rates in the observational
registration studies might be explained by the relative
lower dose of PEGV. To achieve efficacy rates of more
than 90 % during PEGV monotherapy, the average
expected weekly dose is probably above 120–130 mg.
Escape, defined as need to increase the dose of PEGV
because of an increase in IGF-I levels, was reported in
34 % of a Spanish cohort [25]. The majority of patients
were easily controlled with either an increase in PEGV
dose, additional medical treatment or both. Whether this
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increase in the necessary dose of PEGV should be called an
escape is questionable, as most patients were easily con-
trolled and remained controlled on a higher dose of PEGV.
A significant number of these patients escaped from PEGV
within the first 6 months after discontinuation of LA-SSA.
Presumably during this period these patients were actually
still receiving combination treatment, due to the long half-
life of LA-SSAs. The Dutch cohort could not observe this
phenomenon during combination treatment in acromegaly
patients [12].
Co-administration of the highest dose of LA-SSA on top
of PEGV monotherapy appears to reduce the necessary
mean PEGV dose by 50 % [14], although with a high
individual variability [26]. An analysis including eight
patients whose mean IGF-I levels were similar during
PEGV monotherapy, showed that these patients were able
to reduce their PEGV dose from 131.3 ± 36.2 to
62.5 ± 16.7 mg weekly [14]. PEGV dose reduction during
combination treatment might improve cost-effectiveness of
medical treatment in acromegaly and may reduce injection
frequency for patients. However, there are no direct studies
comparing cost-effectiveness of the median required
weekly PEGV dose during mono- and combination
treatment.
Improved quality of life by the addition of PEGV
Physicians tend to be mainly focused on biochemical
parameters as GH and IGF-I levels during treatment of
acromegaly. These parameters are definitely linked to a
better outcome and a lower risk of morbidity and mortality
[27, 28]. A recent French study has described long-term
effects of PEGV on cardiorespiratory and metabolic
comorbidities [29]. They reported that long-term PEGV
treatment improves cardiac function measured by the left
ventricular ejection fraction and the left ventricular mass
index. PEGV also improved the apnea–hypopnea index.
Normalized serum GH and IGF-I levels does not neces-
sarily result in complete resolution of signs and symptoms
[30, 31]. Neggers et al. reported on the results of a
prospective, double blind, placebo controlled, crossover
study, and demonstrated improved quality of life (QoL) in
patients using LA-SSA combined with low-dose PEGV
[31]. QoL was assessed by two acromegaly specific QoL-
questionnaires, the AcroQoL and the PASQ. Improved
QoL was observed without significant changes in IGF-I
levels after addition of PEGV to LA-SSA therapy in
Table 1 Summary of studies reporting on combination treatment
First author, year, (Ref) Design Aim of study No. of
patients
Disease
control (%)
PEGV dose
(mg/weekly)
Duration study
(months)
Van der Lely et al. [24] Case report IGF-I normalization 1 100 280 18
Trainer et al. [17] Randomized
controlled trial
Primary end-point: AEs,
secondary end-point: IGF-I
normalization
29 73 105 9
Van der Lely et al. [14] Prospective
observational study
IGF-I normalization and AEs 57 79 60 7
Bianchi et al. [21] Retrospective
observational study
IGF-I normalization and AEs 27 67 140 30 (median)
Neggers et al. [12] Retrospective
observational study
IGF-I normalization and AEs 112 97 80 59 (median)
Summary of studies reporting on LA-SSA combined with PEGV and the percentage of disease control (normalization of IGF-I levels) and the
required PEGV dose in order to control IGF-I levels. The ACROSTUDY is not included in this table as it includes patients with monotherapy of
PEGV and various other medical combinations with PEGV
LA-SSA long-acting somatostatin analogues, PEGV pegvisomant, IGF-I insulin like growth factor I, AEs adverse events
Fig. 1 Efficacy of combination treatment. Percentages of patients
with IGF-I\ 1.2 9ULN and median PEGV doses (grey line, right
Y-axis) are shown for every individual year during 9 years of
combination treatment, LA-SSA combined with PEGV. Median
PEGV dose is in mg weekly. Cumulative numbers of the included
patients at each treatment year are depicted at the bottom of every bar.
All patients (n = 112) were treated for at least 1 year, 17 patients
were treated for a maximum of 9 years of follow up. LA-SSA: Long-
acting somatostatin analogues; PEGV pegvisomant, IGF-I insulin like
growth factor I. This figure was reproduced with permission from [12]
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patients with normalized IGF-I levels during monotherapy
of LA-SSA. However, a study by Madsen et al. did not
observe an improved QoL in patients using LA-SSA
combined with a low dose of PEGV [32]. Two differences
in the design of the studies might clarify these different
outcomes in QoL; (1) Madsen et al. reduced the dose of
LA-SSA by 50 % before adding low-dose PEGV treat-
ment, while Neggers et al. did not change the LA-SSA
dose; (2) disease specific QoL-questionnaires were used by
Neggers et al. whereas Madsen et al. used QoL-question-
naires which were not disease specific.
An explanation for the observed improvement in QoL
by the addition of low-dose PEGV could be a persistent
systemic acromegaly disease activity during monotherapy
of LA-SSA that has been hypothesized and was called
‘extra-hepatic acromegaly’ [33]. LA-SSA treatment selec-
tively decreases hepatic-IGF-I production by around 20 %
via direct and indirect mechanisms [18, 19, 34]. This might
lead to an overestimation of the efficacy of LA-SSAs to
normalize IGF-I via a reduction in the pathological GH
secretion because of this GH-independent reduction of
IGF-I levels. Therefore, GH actions on extra-hepatic tis-
sues can remain elevated despite normalization of serum
IGF-I levels. LA-SSA reduces portal insulin levels which
decreases hepatic GHR expression only [34]. This results
in a relatively hyper-GH-sensitive state of the other tissues.
Patients report these still excessive GH actions on non-
hepatic tissues such as edema, fatigue and headaches
comparable to the side-effects of high-dose GH replace-
ment therapy in GH deficient subjects. A clinical example
is a Danish study which observed, despite similarly nor-
malized IGF-I levels, that LA-SSA treatment compared
with neurosurgery alone was associated with less sup-
pressed GH levels and less symptom relief [35]. Blocking
non-hepatic GH actions by low-dose PEGV could therefore
be useful in treating this ‘extra-hepatic acromegaly’ [33].
Moreover, PEGV has also been shown to improve insulin
resistance by several mechanisms [36–41], which is bene-
ficial in the presence of LA-SSAs, which are known to
reduce insulin secretion [42, 43].
Pituitary tumor volume
Recent prospective multicenter clinical trial observed
tumor shrinkage in 63 % of primary treated patients with
120 mg Lanreotide Autogel administered every 28 days
[44]. Tumor shrinkage was defined as clinically significant
when C20 % tumor volume reduction was observed after
48 weeks of Lanreotide Autogel administration. While LA-
SSA is successful in reducing tumor volume, previous
concerns were raised whether PEGV might induce growth
of the pituitary adenoma. Despite the fact that in a few
cases an increase in tumor size during PEGV therapy was
reported, there are no data suggesting that PEGV directly
promotes tumor growth [14, 45, 46]. In the GPOS study,
changes in tumor size were systematically monitored in
307 patients, from which 28 patients were treated with
PEGV in combination with LA-SSA, however predomi-
nantly treated with PEGV monotherapy [47]. In eight out
of 307 (2.7 %) an initial increase in tumor size was
reported. In only three of these eight patients a real, but
minor, increase in tumor size after PEGV treatment was
observed [47]. In two of these patients a detectable rebound
increase in tumor size after discontinuation of LA-SSA
therapy was the probable reason of this increase in ade-
noma size. In a Spanish study in 75 patients, 5 (6.7 %)
acromegaly patients were identified with an increase in
pituitary tumor size [48]. All of these patients were pre-
treated with LA-SSA and then switched to PEGV
monotherapy. Noteworthy in this study is that the reference
MRI was made just after LA-SSA was discontinued [48].
Therefore, the reported tumor size increases in this study
may also be explained by the rebound phenomenon after
cessation of LA-SSA treatment. In the Dutch cohort of
acromegaly patients (n = 141) on combination therapy,
growth of the adenoma has been reported in only one
patient, while this growth was already observed before the
addition of PEGV [12]. Moreover, during combined
treatment tumor size shrinkage of more than 20 % of the
largest diameter before and during combination treatment
was observed in 17 % of the patients and the vast majority
had a stable tumor volume. We, therefore, conclude that
PEGV apparently does not influence the natural course of
tumor growth, but ongoing alertness is required to monitor
tumor size by repetitive pituitary imaging.
Side effects
PEGV treatment is generally well tolerated and is
increasingly considered to be safe [9, 49]. As LA-SSAs are
on the market since 1988, more data are available on side
effects. Most commonly reported are gastrointestinal
symptoms such as nausea, vomiting, abdominal pain, bil-
iary sludge or gallstones and diarrhea [50]. Abnormal
glucose metabolism and injection-site reactions are also
described [50]. Lipohypertrophy and hepatotoxicity are the
most frequently reported adverse events during long-term
PEGV treatment. Lipohypertrophy is an increased subcu-
taneous fat deposition around the injection sites of PEGV.
It is suggested that the blockade of GH receptors causes
unopposed insulin effects and, therefore, promotes lipo-
genesis [51]. The symptom arises in 3–15 % of the PEGV
users either during monotherapy or combination treatment
and appeared to be reversible by a more frequent rotation
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of the injection-site [12, 14, 21, 25, 52]. However, in one of
the Dutch patients during combined treatment cosmetic
surgery was necessary in order to reduce the significant
lipohypertrophy [12]. Large observational studies as
ACROSTUDYTM and GPOS, in which patients using
PEGV are included regardless their concomitant medica-
tion, reported 2.2 and 7.4 % lipohypertrophy respectively.
Hepatotoxicity can occur during both PEGV
monotherapy and combination therapy. Cholestasis is a
common side effect of LA-SSA, as it reduces the secretion
of cholecystokinin and motility of the gallbladder and
induces an increase in bile concentration. This results in an
increased risk in development of sludge and gallstones [53,
54]. LA-SSA often induces asymptomatic cholelithiasis,
but an acute cholecystitis has been observed in only a
minority of these patients [55]. The PEGV-induced ele-
vations in hepatocellular enzymes are usually mild and
self-limiting, both during monotherapy PEGV as in com-
bination with LA-SSA [21, 52]. Transient elevated
transaminases (TET) of more than three times the upper
Table 2 Transient elevated transaminases during combination treatment
Sex Age Time between
start PEGV and
TET (months)
PEGV dose
during TET
Peak LFT (9ULN) Follow up
Bili Alk. Phos. c-GT AST ALT
Biering et al. [56]
1 M 43 2.3 10 mg daily NA NA NA 3.1 4.9 Drug withdrawn, norm. of TET
2a F 44 2.2 15 mg daily NA NA NA 11.1 20.8 Drug withdrawn, norm. of TET
Soto Moreno et al. [57]
1 F 31 1.5 10 mg daily 0.3 0.3 1.4 117 80 Drug continued, norm. of TET
Neggers et al. [12]
1 M 41 61.9 30 mg weekly 0.7 0.6 2.0 4.0 4.7 Drug continued, norm. of TET
2 M 39 19.5 300 mg weekly NA 1.0 1.8 5.0 5.5 Drug continued, norm. of TET
3 M 60 2.7 40 mg weekly 0.4 1.2 0.9 4.3 7.0 Drug continued, norm. of TET
4 M 60 58.3 160 mg weekly 0.4 1.2 1.8 4.6 6.5 Drug continued, norm. of TET
5 M 45 3.2 80 mg weekly 1.1 0.5 2.0 3.5 3.9 Drug continued, norm. of TET
6a M 51 3.9 60 mg weekly 2.3 2.9 16.7 16.7 25.8 Drug continued, norm. of TET
7 M 59 3.5 60 mg weekly 0.6 0.8 1.8 2.4 3.6 Drug continued, norm. of TET
8a M 29 18.8 40 mg weekly 5.3 0.9 5.1 4.9 8.0 Drug continued, norm. of TET
9 M 30 0.7 80 mg weekly NA 0.9 0.8 3.1 1.2 Drug continued, norm. of TET
10 M 40 5.8 40 mg weekly 1.6 1.1 4.6 3.1 4.3 Drug continued, norm. of TET
11 M 34 4.9 40 mg weekly 2.0 1.4 8.8 9.5 8.3 Drug continued, norm. of TET
12 M 46 2.9 60 mg weekly 0.9 1.2 4.8 6.3 13.2 Drug continued, norm. of TET
13a M 74 12.8 80 mg weekly 1.3 2.6 11.8 5.6 3.7 Drug continued, norm. of TET
14 M 45 5.8 60 mg weekly 1.3 1.3 6.9 13.7 26.1 Drug withdrawn, norm. of TET
15 F 48 15.4 80 mg weekly 0.8 0.8 1.5 2.9 4.5 Drug continued, norm. of TET
16 F 44 3.4 20 mg weekly 1.0 0.6 0.9 7.5 10.0 Drug continued, norm. of TET
Re-exposure to PEGV: caused a
2nd TET period
17 F 54 5.5 60 mg weekly 0.7 0.7 2.7 2.8 4.0 Drug continued, norm. of TET
18 F 41 4.8 60 mg weekly NA NA 3.9 NA 4.6 Drug continued, norm. of TET
19 F 61 11.3 160 mg weekly NA 1.1 4.1 2.4 3.7 Drug continued, norm. of TET
20 F 67 2.2 20 mg weekly NA 0.9 2.3 2.8 3.7 Drug continued, norm. of TET
Re-exposure to PEGV: caused a
2nd TET period
21 F 41 2.5 40 mg weekly 1.3 0.7 1.3 8.4 11.7 Drug continued, norm. of TET
22 F 27 4.1 60 mg weekly NA 1.0 1.5 4.0 4.8 Drug continued, norm. of TET
Description of TET patients during medical treatment with LA-SSA combined with PEGV
a Elevated transaminases due to proven cholecystolithiasis
LFT liver function tests, TET transient elevated transaminases, LA-SSA long-acting somatostatin analogues, PEGV pegvisomant, 9ULN times
upper limit of normal, Bili total bilirubin, Alk. Phos alkaline phosphatase, c-GT c-glutamyltranspeptidase, AST aspartate aminotransaminase, ALT
alanine aminotransferase, NA not available
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limit of normal ([3 9ULN) were observed in 11.3–13.5 %
of the patients using LA-SSA combined with PEGV [12,
21]. One Italian study compared long-term treatment of
PEGV alone with PEGV in combination with LA-SSA
regarding to TET [21]. Incidence of TET during
monotherapy of PEGV was reported in 14.3 % of the
patients, while this incidence was 11.1 % in the combined
group. In the Dutchcohort (N = 19/141) all cases were
transient without PEGV dose adaptation or discontinuation
of the drug, except for one patient [12]. More details about
TET patients are shown in Table 2. The development of
TET was not PEGV dose-dependent. The ACROSTU-
DYTM and GPOS reported lower incidence rates of TET
[3 9ULN, 2.5 and 5.2 % respectively. The most recent
ACROSTUDYTM paper, the Italian experience as it
includes only patients registered in Italy (n = 341),
reported an increase of TET[5 9ULN in 0.9 % of the
patients after 3 months of PEGV use and TET normalized
after PEGV was withdrawn.
More frequent out-patient clinic visits and, thereby,
more frequent assessments of ALT and AST might explain
the observed differences in the incidence of TET, as the
elevations in transaminases are transient and will pass
unnoticed when follow-up intervals are wider. A previ-
ously described association between TET and Gilbert’s
polymorphism (UGT1A1*28) in a Spanish study (n = 36)
[58], was not confirmed by the Dutch cohort (n = 141)
[12].
Conclusion
Advantages of the combination treatment of LA-SSA and
PEGV are high efficacy rates in acromegaly patients,
provided that the appropriate PEGV dose is used, which
seems to be lower in the combined treatment than during
PEGV monotherapy. Tumor shrinkage and cessation of
tumor volume was observed in the vast majority of the
patients. Disadvantages of combining LA-SSA with PEGV
is the economic burden of life-long administration of
expensive medicaments and side effects of both drugs can
occur. Furthermore, in patients treated with LA-SSA and
PEGV, only IGF-I levels can be interpreted as some
commercial GH assays are not able to distinguish between
GH and PEGV. Although, the combination of LA-SSA and
PEGV is generally well tolerated and side effects as lipo-
hypertrophy and elevated transaminase are usually mild
and transient, clinical attention towards side effects remain
obligate. Therefore, we recommend to frequently rotate the
PEGV injection-site as this reduces the risk of (serious)
lipohypertrophy. With respect to the elevated transaminases
[3 9ULN, we recommend assessing liver enzymes levels
with the same frequency as described by the label of
PEGV. Cholelithiasis must be excluded by an ultrasound of
the liver and gallbladder. In patients with TET[10 9ULN,
we also recommend performing a liver biopsy and dis-
continuing PEGV in case of drug-induced hepatitis. PEGV-
induced tumor size increase has not been observed to date,
but repetitive pituitary imaging remains mandatory.
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